Safety of Nebulized Combination Therapy BromAc® in COVID-19 Respiratory Disease
Phase 1
- Conditions
- COVID-19 PneumoniaCOVID-19Ventilator Associated PneumoniaCOVID-19 Acute Respiratory Distress Syndrome
- Interventions
- First Posted Date
- 2022-02-28
- Last Posted Date
- 2022-02-28
- Lead Sponsor
- Mucpharm Pty Ltd
- Target Recruit Count
- 30
- Registration Number
- NCT05258682
Nebulised BromAc in Healthy Volunteers
Phase 1
Completed
- Conditions
- Mucus; PlugCOVID-19 Acute Respiratory Distress SyndromeBromelains Adverse ReactionCOVID-19 PneumoniaAcetylcysteine Adverse Reaction
- Interventions
- First Posted Date
- 2022-02-02
- Last Posted Date
- 2022-09-15
- Lead Sponsor
- Mucpharm Pty Ltd
- Target Recruit Count
- 12
- Registration Number
- NCT05220605
- Locations
- 🇦🇺
St George Hospital, Kogarah, New South Wales, Australia
BromAc for Recurrent Peritoneal Mucinous Tumour or Pseudomyxoma Peritonei
Phase 2
- Conditions
- Mucinous AdenocarcinomaPseudomyxoma PeritoneiPeritoneal CancerMucinous Tumor
- Interventions
- First Posted Date
- 2019-06-06
- Last Posted Date
- 2022-03-15
- Lead Sponsor
- Mucpharm Pty Ltd
- Target Recruit Count
- 62
- Registration Number
- NCT03976973
© Copyright 2025. All Rights Reserved by MedPath